Lead Product(s) : Survodutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Zealand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The dual agonist BI 456906 has the potential to be a new, once-weekly treatment that may offer therapeutically relevant benefits compared to currently available treatments.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
February 06, 2021
Lead Product(s) : Survodutide
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Zealand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable